Trial · NCT06484829
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT06484829, Phase 1, Phase 2, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Trials, record NCT06484829. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06484829
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- NCT number
- NCT06484829
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 144 participants, estimated
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2, Purinostat Mesylate 8.4 mg/m2
- First posted
- 2024-07-03
- Last updated
- 2025-04-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-limiting toxicity (DLT) | Day 21/Day 28 | One or more unacceptable toxic reactions following administration of the drug, resulting in the inability to continue increasing the dose or prolonging the dosing cycle |
| Primary | Maximum Tolerated Dose (MTD) | Day 21/Day 28 | The maximum dose or concentration of a drug that does not cause death in experimental animals in experiments other than acute toxicity animal experiments (short-term repetitive experiments, subchronic toxicity experiments, chronic toxicity experiments). |
| Primary | Objective remission rate (ORR) | Day 21/Day 28 | Defined as the proportion of subjects achieving a strict complete remission (sCR) + complete remission (CR) + very good partial remission (VGPR) + partial remission (PR); |
| Secondary | Complete Remission Rate (CRR) | Day 21/Day 28 | Proportion of subjects with sCR+CR |
| Secondary | Duration of efficacy (DOR) | Day 21/Day 28 | Duration of first remission (PR and above) to disease progression or death; |
| Secondary | Time to Relief (TTR) | Day 21/Day 28 | Time from first dose to PR and beyond |
| Secondary | Progression-free survival (PFS) | Day 21/Day 28 | Time from first dose to disease progression or death |
| Secondary | Overall survival (OS) | Day 21/Day 28 | Time from first dose to death from all causes |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06484829
GET https://conductscience.org/api/trials/v1/NCT06484829/registered